Resiliva is identified on this website as a product containing resmetirom in stated 80 mg and 100 mg strengths.
| Product characteristic | Information |
|---|---|
| Product | Resiliva |
| Active ingredient | Resmetirom |
| Stated strengths | 80 mg and 100 mg |
| Drug class | THR-β agonist |
| Therapeutic area | MASH/NASH with liver fibrosis |
| Route | orally |
| Reference product | Rezdiffra |
| Original development history | VIA/Roche; later Madrigal |
| Resiliva manufacturer | Everest Pharmaceuticals Ltd. |
Resmetirom activates THR-β in the liver and influences hepatic lipid metabolism.
Reference product
Rezdiffra is the established resmetirom reference product. FDA approved it in 2024, and the EMA granted conditional EU authorization in 2025.
Regulatory status
The regulatory status of Resiliva itself is Everest Pharmaceuticals Ltd.
Safety
Important resmetirom risks include hepatotoxicity and gallbladder-related adverse reactions. Drug interactions involving CYP2C8 and certain statins are also clinically relevant.
Product verification
The actual product packaging, manufacturer and authorization documentation should be checked before use.